• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Quick Take: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN)

byDonna LeetandAliya Ramjaun
July 1, 2019
in Oncology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal neoplasm that arises in the joints, bursae, or tendon sheaths. The standard treatment is surgical resection, but recurrence is common. Repeated surgery in these patients also carries a risk of increasing morbidity and mortality. Unfortunately, no systemic therapies currently exist. Pexidartinib is a novel small molecule tyrosine-kinase inhibitor which has shown clinical efficacy against recurrent or inoperable TGCT in a phase 1 study. In part one of this randomized controlled trial, 120 patients with advanced TGCT for whom surgery was not recommended were assigned to receive pexidartinib therapy or placebo to study the impact on overall disease response (complete or partial response) at week 25 based on MRI. In part two of the study, all patients received pexidartinib. Due to the emergence of mixed or cholestatic hepatotoxicity, the data monitoring committee stopped enrollment six patients short of the target study population of 126. Researchers found that more patients in the pexidartinib group achieved overall disease response at week 25 than in the placebo group (39% vs. 0%, difference 39%, 95% CI 27% to 53%, p<0.0001). At 6 months, no patient who responded to pexidartinib at week 25 had progressed. Serious adverse events occurred in 13% of patients in the pexidartinib group and in 2% of patients in the placebo group. These cases included three patients in the pexidartinib group who experienced mixed or cholestatic hepatotoxicity, two of which recovered, while the other case lasted 7 months and was confirmed by liver biopsy. Hair color changes (67%), fatigue (54%), and aspartate aminotransferase increase (39%) were the most frequent pexidartinib-associated adverse events. This study was limited by early termination of patient enrollment. Overall, this study suggests that pexidartinib therapy may have significant clinical efficacy in the treatment of advanced TGCT. However, the potential therapeutic benefits of pexidartinib should be weighed against the risk of mixed and cholestatic hepatotoxicity.

Click to read the study in Lancet

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: giant cell tumor of the tendon sheath (GCTTS)pexidartinibtenosynovial giant cell tumor (TGCT)tyrosine kinase inhibitor
Previous Post

Effective adolescent mental health programs incorporate interpersonal skills, emotional regulation, and drug education

Next Post

2 Minute Medicine Rewind July 1, 2019

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia
StudyGraphics

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

February 26, 2021
#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
StudyGraphics

#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

January 10, 2020
Severity of emphysema on pulmonary CT may predict lung cancer location
Oncology

Osimertinib associated with longer overall survival versus comparator EGFR-TKIs

December 24, 2019
Next Post
Aspirin therapy linked to fewer cases of preeclampsia

2 Minute Medicine Rewind July 1, 2019

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Quick Take: Association Between Preoperative Opioid and Benzodiazepine Prescription Patterns and Mortality After Noncardiac Surgery

Placebo formulation impacts effectiveness of pain control in osteoarthritis

Tanezumab provides modest benefit for osteoarthritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.